 | Up a level |
Fleeman, Nigel 
ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Duarte, Rui, Richardson, Marty ORCID: 0000-0002-7097-8704, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Boland, Angela ORCID: 0000-0002-5435-8644, Kotas, Eleanor, McEntee, Joanne and Thorp, Nicky
(2019)
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
PHARMACOECONOMICS-OPEN, 3 (3).
pp. 293-302.
Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Duarte, Rui, Chaplin, Marty ORCID: 0000-0002-7097-8704, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Boland, Angela ORCID: 0000-0002-5435-8644, Kotas, Eleanor, Mcentee, Joanne and Thorp, Nicky
(2017)
Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen.
[Report]
Hall, Benjamin James, Bhojwani, Ajay Ashok, Wong, Helen, Law, Andrea, Flint, Helen, Ahmed, Eliyaz, Innes, Helen, Cliff, Joanne, Malik, Zaf, O'Hagan, Julie Elizabeth et al (show 14 more authors)
(2022)
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.
BREAST JOURNAL, 2022.
7146172-.
Olsson-Brown, Anna, Piskilidis, Pavlos, O'Hagan, Julie, Thorp, Nicky, Robson, Peter, Innes, Helen, Wong, Helen, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Jackson, Richard, Kiernan, Tamara et al (show 3 more authors)
(2019)
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.
BREAST, 44.
pp. 94-100.